Efficacy of Esketamine among patients with treatment resistant depression in a 'real world' health-care setting in Israel.
Journal of psychiatric research June 1, 2024 Lior Dvorak, Esther Bloemhof-Bris, Assaf Shelef et al. 9 citations
About 60% of patients with treatment-resistant depression who completed an acute phase of esketamine therapy went on to finish a maintenance phase. Depressive symptoms, measured with the Quick Inventory of Depressive Symptomatology, showed linear improvement during both phases. A sub-analysis of patients with a comorbid personality disorder revealed a similar improvement pattern in the acute phase but milder improvement during maintenance compared to other patients. The findings support the use of esketamine for treatment-resistant depression, including for those with comorbid personality disorder or a history of electroconvulsive therapy.